The new in-vitro diagnostic regulation (2017/746/eu)
challenge or an opportunity for manufacturers and key stakeholders
Journal name: World Journal of Pharmaceutical Research
Original article title: The new in-vitro diagnostic regulation (2017/746/eu)
The WJPR includes peer-reviewed publications such as scientific research papers, reports, review articles, company news, thesis reports and case studies in areas of Biology, Pharmaceutical industries and Chemical technology while incorporating ancient fields of knowledge such combining Ayurveda with scientific data.
This page presents a generated summary with additional references; See source (below) for actual content.
Subtitle: challenge or an opportunity for manufacturers and key stakeholders
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Hardeep Singh Kohli and Supriya Agnihotri
Download the PDF file of the original publication
World Journal of Pharmaceutical Research:
(An ISO 9001:2015 Certified International Journal)
Full text available for: The new in-vitro diagnostic regulation (2017/746/eu)
Source type: An International Peer Reviewed Journal for Pharmaceutical and Medical and Scientific Research
Doi: 10.20959/wjpr202210-24993
Copyright (license): WJPR: All rights reserved
Summary of article contents:
Introduction
The European Union (EU) has recently implemented the In Vitro Diagnostic Regulation (IVDR) 2017/746, which changes the regulatory landscape for medical and in vitro diagnostic devices. This regulatory update was spurred by significant incidents involving medical devices that highlighted flaws in the previous directives, prompting a need for a more robust framework to ensure patient safety and the effectiveness of medical products. As manufacturers and stakeholders navigate this new environment, discussions arise regarding whether these regulations present challenges or opportunities within the industry.
Enhanced Regulatory Oversight
One of the key facets of the IVDR is the significant increase in regulatory oversight, particularly concerning Notified Bodies (NBs). Under the previous directive, many in vitro diagnostic devices could be self-declared by manufacturers. However, with the IVDR's new risk-based classification system, a substantial number of devices—estimated at about 80%—will now require external assessment by NBs. This shift places a heavy burden on NBs, with predictions indicating a potential workload increase of up to 780% for those involved in recertification processes. The transition is compounded by a demonstrated shortage of designated NBs, which poses risks to timely compliance and market readiness for many manufacturers.
Impact on Small and Medium-sized Enterprises
The IVDR's enactment poses particular threats to small and medium-sized enterprises (SMEs), which may struggle most with the increased costs and resources required for compliance. Many SMEs face the daunting task of realigning their product portfolios in response to reclassification and heightened scrutiny, potentially leading to significant reductions in the number of devices they can market. In some cases, SMEs might abandon certain products altogether, leading to mergers and acquisitions as larger companies seek to fill gaps in their offerings. The increased financial burden raises concerns about reduced competition and innovation within this sector, as smaller entities often serve as key drivers of new ideas and technologies.
Strengthened Clinical Evidence Requirements
A critical update with the IVDR is the rigorous demand for clinical evidence to support product performance and safety throughout the lifecycle of the device. Manufacturers are required to comprehensively document scientific validity, analytical performance, and clinical performance, resulting in a more integrated approach to compliance and oversight. This focus aims to ensure that all devices on the market are backed by solid evidence and maintain ongoing evaluations of their efficacy and safety. While this enhances the integrity of diagnostics, it raises challenges for manufacturers, particularly in terms of resource allocation and expertise in producing the necessary clinical data.
Conclusion
The implementation of the IVDR represents a paradigm shift in the regulatory framework governing in vitro diagnostics within the EU. While it aims to enhance patient safety and product efficacy through stronger oversight and demanding evidence requirements, it introduces significant challenges, particularly for smaller manufacturers. The effective execution of these regulations relies on the capacity of both manufacturers and regulatory bodies to adapt swiftly and efficiently. Stakeholders within the medical device sector must prepare for a transformation that will not only reshape their compliance strategies but also affect their competitive landscape and innovation potential in diagnostics.
FAQ section (important questions/answers):
What is the main purpose of the new IVDR?
The new In Vitro Diagnostic Regulation (IVDR) aims to enhance diagnostic testing quality, ensure patient safety, and increase product transparency in the EU market through stricter regulatory oversight.
How does the IVDR affect small and medium-sized enterprises?
Small and medium-sized enterprises may face challenges in compliance costs, potentially leading to reduced product offerings or market exits due to stringent IVDR requirements.
What changes were made regarding Notified Bodies in the IVDR?
The IVDR increases Notified Bodies' oversight, requiring more devices to undergo rigorous assessment, resulting in a significantly higher workload for these organizations.
What are the expected consequences of the IVDR on product offerings?
Manufacturers may streamline their portfolios, prioritizing high-demand products, which could lead to some diagnostic tests being discontinued due to increased regulatory burdens.
How does the IVDR improve patient safety?
The IVDR mandates greater clinical evidence, robust post-market surveillance, and a unique device identification system, all of which contribute to enhanced safety and performance standards for diagnostic devices.
What concerns have been raised regarding the transition to IVDR?
Concerns include potential delays in product recertification, the risk of thousands of IVDs being removed from the market, and the overall readiness of stakeholders for the new regulations.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “The new in-vitro diagnostic regulation (2017/746/eu)”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Kohli:
Kohli refers to Hardeep Singh Kohli, an author in the study of In-Vitro Diagnostic Regulation (IVDR). His insights draw upon his expertise in regulatory affairs and the impact of European regulations on manufacturers and stakeholders, highlighting the balance between market opportunities and regulatory challenges in the medical device sector.
2) Performance:
Performance pertains to the effectiveness and reliability of in-vitro diagnostic devices as mandated by the new regulations. In this context, assessing the performance of medical devices includes their safety, efficacy, and the scientific validation necessary for compliance, thereby ensuring better outcomes for patient care.
3) Post:
Post refers to post-market surveillance, an essential aspect highlighted in the IVDR. This involves monitoring the performance of medical devices after they have been placed on the market to ensure ongoing compliance with safety and effectiveness standards, thus maintaining patient safety over the product lifecycle.
4) Quality:
Quality refers to the standard of both the medical devices themselves and the processes involved in their creation. Under the IVDR, ensuring high quality is essential, where manufacturers must maintain a quality management system to oversee the entire development and lifecycle of diagnostic devices.
5) Medium:
Medium refers to the classification of enterprises, particularly those defined as small and medium-sized enterprises (SMEs) in the healthcare sector. The IVDR's implications are profound for SMEs, as they face challenges adapting to stringent regulations, potentially impacting their market presence and innovation capabilities.
6) India:
India is significant in the context of this study as a region where medical technology and regulations are increasingly becoming relevant. It has a growing market for in-vitro diagnostics, thus being influenced by global regulatory standards like the EU IVDR, affecting local manufacturers and healthcare stakeholders.
7) Rules:
Rules refer to the regulatory frameworks established under the IVDR. They dictate the requirements for the classification, assessment, and conformity evaluation of in-vitro diagnostic devices, ultimately serving to enhance patient safety and ensure that only reliable products are allowed in the market.
8) Study (Studying):
Study signifies the research conducted to analyze the implementation and effects of the IVDR on stakeholders, including manufacturers and healthcare providers. Through comprehensive examination, it aims to highlight both challenges and opportunities presented by the new regulatory landscape in medical diagnostics.
9) Life:
Life in this context refers to the product lifecycle management required by the IVDR. Manufacturers are mandated to ensure ongoing compliance, safety, and performance evaluation throughout a device's entire life cycle, from its initial approval to its everyday use in healthcare settings.
10) Evolution:
Evolution denotes the development and transformation of the regulatory landscape surrounding in-vitro diagnostics over the years. The shift from previous directives to the IVDR illustrates a fundamental change in approach to ensure public safety and device effectiveness in the rapidly changing medical technology field.
11) Thomas:
Thomas refers to Dr. Thomas Hafen, a key figure mentioned in the study who discusses the challenges faced by SMEs in meeting regulatory demands. His perspective highlights concerns regarding the financial burden on smaller companies, which may stifle innovation and market competition in diagnostics.
12) Road:
Road reflects the metaphorical journey of adaptation and transformation that stakeholders must undertake in response to the new IVDR regulations. This involves re-evaluating strategies, aligning product portfolios with regulatory requirements, and ensuring compliance to maintain a competitive edge in the diagnostic market.
13) Hand:
Hand emphasizes the collaborative efforts required among stakeholders, including manufacturers, regulatory bodies, and healthcare providers, in implementing the new regulations. Effective communication and cooperation among parties are essential to navigate the complexities of the IVDR and ensure successful compliance and patient safety.
14) New Delhi:
New Delhi is mentioned as the location of Point of Care Biosystem, where Hardeep Singh Kohli works. It serves as a significant hub for regulatory affairs and medical technology in India, reflecting the increasing integration of global standards like the IVDR into local practices.
15) Transformation (Transform, Transforming):
Transformation refers to the profound changes that the IVD industry is undergoing due to the implementation of IVDR. This includes regulatory shifts, innovations in device design and function, and a reimagining of how diagnostic products are developed, assessed, and used in healthcare.
16) Discussion:
Discussion pertains to the critical dialogue surrounding the implications of the IVDR among stakeholders. It encompasses the exploration of challenges, solutions, and strategic considerations for manufacturers and regulatory bodies as they adapt to the new landscape and work to maintain innovation.
17) Medicine:
Medicine, in this context, refers to the field that intersects with diagnostics, emphasizing the significance of accurate testing in diagnosing and treating patients. The IVDR's enhancement of diagnostic standards directly influences how effectively medical treatments can be delivered.
18) Disease:
Disease indicates the important role diagnostics play in detecting and managing health conditions. The IVDR aims to improve the accuracy and reliability of diagnostic tests, which is critical in the early detection and treatment of various diseases, thereby enhancing patient outcomes.
19) Company:
Company refers to enterprises involved in the development and manufacturing of in-vitro diagnostic devices. The IVDR imposes new regulatory challenges and requires companies to reassess their product offerings, streamline processes, and ensure compliance with heightened safety and performance standards.
20) Punjab:
Punjab is mentioned as the location of Chandigarh College of Pharmacy where at least one of the authors is affiliated. This reflects the increasing importance of educational institutions in shaping the understanding of medical regulations and their implications for public health.
21) Delhi:
Delhi, as a significant urban center in India, is relevant as a location for regulatory affairs and the biotechnology market. With various startups and established companies based there, the city plays a crucial role in the developments related to in-vitro diagnostics and technology.
22) Nakar:
Nagar appears as part of the address for Chandigarh College of Pharmacy, indicating its geographical and institutional relevance. Understanding local institutions is vital for grasping the landscape of medical education and research in relation to regulatory advancements in diagnostics.
23) Reliability:
Reliability signifies the importance of consistent and dependable performance from in-vitro diagnostic devices as mandated by the IVDR. Ensuring device reliability is crucial for obtaining credible clinical results, thereby influencing patient decisions and treatment efficacy in healthcare settings.
24) Developing:
Developing in this context refers to the ongoing evolution of regulatory frameworks and medical technologies. It underscores the dynamic nature of the healthcare sector, highlighting the need for adaptive strategies among manufacturers to keep pace with regulatory changes and technological advancements.
25) Science (Scientific):
Science reflects the rigorous methodologies and evidence-based practices required by the IVDR. Compliance necessitates scientifically sound performance evaluations and clinical validations, which ultimately support the reliability and trustworthiness of diagnostic tests used in healthcare.
26) Knowledge:
Knowledge emphasizes the essential information and expertise needed by stakeholders, including manufacturers and notified bodies, to navigate the complex requirements of the IVDR. Increased knowledge sharing will be pivotal in achieving compliance and fostering innovation in the diagnostic field.
27) Agnihotrin (Agni-hotri, Agni-hotrin, Agnihotr, Agnihotri):
Agnihotri refers to Supriya Agnihotri, a co-author of the study. Her involvement contributes additional expertise and perspective to the analysis of the IVDR's impact, thus enriching the understanding of regulatory issues within the context of in-vitro diagnostics.
28) Lakshman (Laksman):
Lakshman is mentioned as an expert commenting on the shortcomings in the regulatory process and the anticipated challenges in the transition to the IVDR. His insights underline the need for systematic improvements in the regulatory framework to support timely device approvals.
29) Activity:
Activity references the ongoing processes that stakeholders must engage in to comply with the new IVDR regulations. This includes continuous monitoring, risk management, and post-market surveillance activities that ensure medical devices maintain safety and effectiveness throughout their lifecycle.
30) Language:
Language pertains to the necessity of clear communication among diverse stakeholders involved in implementing IVDR. The regulations require effective dialogue and documentation in various languages, ensuring all parties understand the compliance requirements and can engage effectively in discussions.
31) Meeting:
Meeting signifies the collaborative interactions among regulatory authorities, manufacturers, and other key stakeholders to discuss the implications of IVDR. It is crucial for aligning strategies and addressing challenges in implementing the new regulatory framework effectively.
32) Falling:
Falling highlights the anticipated decline in the number of compliant in-vitro diagnostic devices due to the stringent requirements of the IVDR. This reduction poses a potential risk to patient care and access to essential diagnostic tests, particularly among smaller manufacturers.
33) Worry (Worried, Worrying):
Worried indicates the concerns expressed by various stakeholders, especially smaller companies, regarding the financial and operational impacts of IVDR. The regulatory burden and increased costs contribute to anxieties about market competitiveness and the sustainability of smaller enterprises.
34) Repair:
Repair signifies the ongoing need for maintaining and updating regulatory practices and device standards in response to evolving medical challenges. As new scientific insights and technologies emerge, continuous adjustment ensures that diagnostics remain relevant and effective in addressing health issues.
35) Party:
Party refers to the various stakeholders involved in the IVDR regulatory process, including manufacturers, notified bodies, healthcare providers, and regulatory authorities. Successful implementation of the regulations relies on understanding and collaboration among all parties to optimize compliance and innovation.
36) Catching (Catch, Catched):
Catch refers to the need for stakeholders to adapt to the fast-paced changes introduced by the IVDR. Those who are quick to catch up on regulatory requirements will be better positioned to succeed in the market amidst heightened competition and evolving healthcare landscapes.
37) Line:
Line indicates the conceptual division between compliance and innovative development in the medical device sector. Maintaining this line is crucial for balancing regulatory adherence while fostering the advancement of new technologies that can improve patient outcomes.
38) Fire:
Fire signifies a sense of urgency in addressing the upcoming compliance demands associated with the IVDR. Manufacturers and stakeholders must act swiftly to implement necessary changes and meet the new standards to remain competitive and ensure patient safety.
39) Wolf:
Wolf is mentioned as part of a figure's reference in the study discussing timelines related to IVDR transition. His contributions may pertain to providing insights on the operational perspectives of regulatory shifts, as well as their impact on business models in diagnostics.
Other Science Concepts:
Discover the significance of concepts within the article: ‘The new in-vitro diagnostic regulation (2017/746/eu)’. Further sources in the context of Science might help you critically compare this page with similair documents:
Transition period, Performance evaluation, Clinical Evidence, Risk Management, Post Marketing Surveillance, Mergers and Acquisitions, High-risk devices.